BMRN · Biomarin Pharmaceutical Inc · Webcasts, Transcripts & Audio
$57.23
+0.53 (+0.93%)
At close · Nov 13
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$11.09B
Shares
193.69M
Volume · Nov 13
1.47M
Avg daily vol (3M)
2.19M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Biomarin Pharmaceutical Inc Webcasts
Earnings calls, investor updates, investor days and conferences for Biomarin Pharmaceutical Inc (BMRN), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Conference
Investor event
2026-11-17
Biomarin Pharmaceutical Inc (BMRN) November 17, 2026 Conference
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-11-16
Biomarin Pharmaceutical Inc (BMRN) November 16, 2026 Conference
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-11-11
Biomarin Pharmaceutical Inc (BMRN) November 11, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q3
2026-11-02
Biomarin Pharmaceutical Inc (BMRN) Q3 2026 Earnings Call Transcript
Confident tone
Updated guidance, order timing, and geopolitical disruption
Voxzogo and skeletal conditions expansion
Metabolic conditions performance
Revenue
$1.02B
▲ 32% YoY Diluted EPS
$-0.63
Gross margin
80.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-09-10
Biomarin Pharmaceutical Inc (BMRN) September 10, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-09
Biomarin Pharmaceutical Inc (BMRN) September 9, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-08-12
Biomarin Pharmaceutical Inc (BMRN) August 12, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-06
Biomarin Pharmaceutical Inc (BMRN) Q2 2026 Earnings Call Transcript
Confident tone
Voxzogo (Vosoritide) Performance and Expansion
Galafold (Fabry Disease) Commercial Outlook
Amicus Acquisition Integration
Revenue
$989.71M
▲ 19.9% YoY Diluted EPS
$0.23
▼ 81.3% YoY Gross margin
79.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-04
Biomarin Pharmaceutical Inc (BMRN) Q1 2026 Earnings Call Transcript
Confident tone
Voxzogo commercial momentum
Amicus acquisition and integration
Enzyme Therapies growth
Revenue
$766.21M
▲ 2.8% YoY Diluted EPS
$0.54
▼ 43.2% YoY Gross margin
74.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-23
Biomarin Pharmaceutical Inc (BMRN) Q4 2025 Earnings Call Transcript
Confident tone
Revenue growth and franchise performance
Voxzogo label expansion (hypochondroplasia)
Inorganic growth via acquisitions
Revenue
$874.57M*
▲ 17% YoY Gross margin
68.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-10-27
Biomarin Pharmaceutical Inc (BMRN) Q3 2025 Earnings Call Transcript
Positive tone
VOXZOGO growth and achondroplasia franchise
Hypochondroplasia label expansion
Enzyme Therapies business unit
Revenue
$776.13M
▲ 4.1% YoY Diluted EPS
$-0.16
▼ 129.1% YoY Gross margin
82.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-04
Biomarin Pharmaceutical Inc (BMRN) Q2 2025 Earnings Call Transcript
Confident tone
Revenue growth and full-year guidance raise
BMN 333 (long-acting achondroplasia therapy) Phase II/III
BMN 401 / Inozyme acquisition and ENERGY III trial
Revenue
$825.41M
▲ 15.9% YoY Diluted EPS
$1.23
▲ 123.6% YoY Gross margin
81.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-01
Biomarin Pharmaceutical Inc (BMRN) Q1 2025 Earnings Call Transcript
Confident tone
VOXZOGO franchise
Pipeline and R&D
Revenue and earnings growth
Revenue
$745.14M
▲ 14.8% YoY Diluted EPS
$0.95
▲ 106.5% YoY Gross margin
79.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-19
Biomarin Pharmaceutical Inc (BMRN) Q4 2024 Earnings Call Transcript
Confident tone
VOXZOGO growth and franchise leadership
Pipeline catalysts and clinical data
Enzyme therapy franchise durability
Revenue
$747.31M*
▲ 15.6% YoY Gross margin
81.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-29
Biomarin Pharmaceutical Inc (BMRN) Q3 2024 Earnings Call Transcript
Confident tone
VOXZOGO growth and Skeletal Conditions franchise
BMN 333 long-acting CNP development
Enzyme Therapies portfolio performance
Revenue
$745.74M
▲ 28.3% YoY Diluted EPS
$0.55
▲ 161.9% YoY Gross margin
74.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-05
Biomarin Pharmaceutical Inc (BMRN) Q2 2024 Earnings Call Transcript
Confident tone
VOXZOGO commercial momentum and label expansion
ROCTAVIAN strategic reset and focused launch
Revenue timing dynamics between orders and patients
Revenue
$712.03M
▲ 19.6% YoY Diluted EPS
$0.55
▲ 89.7% YoY Gross margin
81.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-04-24
Biomarin Pharmaceutical Inc (BMRN) Q1 2024 Earnings Call Transcript
Positive tone
Voxzogo growth and label expansion
Roctavian commercial challenges
Investor Day strategy reveal
Revenue
$648.83M
▲ 8.8% YoY Diluted EPS
$0.46
▲ 70.4% YoY Gross margin
80.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-22
Biomarin Pharmaceutical Inc (BMRN) Q4 2023 Earnings Call Transcript
Confident tone
VOXZOGO commercial acceleration
Financial performance and 2024 guidance
ROCTAVIAN launch and uptake
Revenue
$646.21M*
▲ 20.2% YoY Gross margin
78.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-01
Biomarin Pharmaceutical Inc (BMRN) Q3 2023 Earnings Call Transcript
Revenue
$581.33M
▲ 15% YoY Diluted EPS
$0.21
Gross margin
78.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-07-31
Biomarin Pharmaceutical Inc (BMRN) Q2 2023 Earnings Call Transcript
Revenue
$595.27M
▲ 11.5% YoY Diluted EPS
$0.29
▲ 93.3% YoY Gross margin
78.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-04-26
Biomarin Pharmaceutical Inc (BMRN) Q1 2023 Earnings Call Transcript
Revenue
$596.41M
▲ 14.8% YoY Diluted EPS
$0.27
▼ 57.1% YoY Gross margin
77.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-27
Biomarin Pharmaceutical Inc (BMRN) Q4 2022 Earnings Call Transcript
Revenue
$537.54M*
▲ 19.5% YoY Gross margin
72.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-10-26
Biomarin Pharmaceutical Inc (BMRN) Q3 2022 Earnings Call Transcript
Revenue
$505.34M
▲ 23.6% YoY Diluted EPS
$-0.04
Gross margin
77.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-25
Biomarin Pharmaceutical Inc (BMRN) Q2 2022 Earnings Call Transcript
Revenue
$533.80M
▲ 6.4% YoY Diluted EPS
$0.15
▲ 114.3% YoY Gross margin
76.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-04-27
Biomarin Pharmaceutical Inc (BMRN) Q1 2022 Earnings Call Transcript
Revenue
$519.36M
▲ 6.9% YoY Diluted EPS
$0.63
▲ 600% YoY Gross margin
77.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-23
Biomarin Pharmaceutical Inc (BMRN) Q4 2021 Earnings Call Transcript
Revenue
$449.81M*
▼ 0.5% YoY Gross margin
73.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-10-27
Biomarin Pharmaceutical Inc (BMRN) Q3 2021 Earnings Call Transcript
Revenue
$408.74M
▼ 14.3% YoY Diluted EPS
$-0.20
▼ 105% YoY Gross margin
74.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-07-28
Biomarin Pharmaceutical Inc (BMRN) Q2 2021 Earnings Call Transcript
Revenue
$501.69M
▲ 16.8% YoY Diluted EPS
$0.07
Gross margin
74.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-04-29
Biomarin Pharmaceutical Inc (BMRN) Q1 2021 Earnings Call Transcript
Revenue
$486.03M
▼ 3.2% YoY Diluted EPS
$0.09
▼ 79.5% YoY Gross margin
75.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-25
Biomarin Pharmaceutical Inc (BMRN) Q4 2020 Earnings Call Transcript
Revenue
$452.12M*
▼ 0.5% YoY Gross margin
72.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Biomarin Pharmaceutical Inc (BMRN) Q3 2020 Earnings Call Transcript
Revenue
$476.78M
▲ 3.4% YoY Diluted EPS
$4.01
▲ 1236.7% YoY Gross margin
60.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-04
Biomarin Pharmaceutical Inc (BMRN) Q2 2020 Earnings Call Transcript
Revenue
$429.49M
▲ 10.8% YoY Diluted EPS
$-0.16
Gross margin
77.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-04-29
Biomarin Pharmaceutical Inc (BMRN) Q1 2020 Earnings Call Transcript
Revenue
$502.07M
▲ 25.3% YoY Diluted EPS
$0.44
Gross margin
77.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-26
Biomarin Pharmaceutical Inc (BMRN) Q4 2019 Earnings Call
Revenue
$454.44M*
▲ 28.7% YoY Gross margin
78.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–34 of 34 webcasts
Key facts
CIK
1048477
CUSIP
09061G101
13F (30d)
453 filings
397 filers
Visit website
Investor relations